138 related articles for article (PubMed ID: 8319208)
1. Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells--preclinical studies in a relevant rat model for human acute myelocytic leukemia.
el-Beltagi HM; Martens AC; Lelieveld P; Haroun EA; Hagenbeek A
Cancer Res; 1993 Jul; 53(13):3008-14. PubMed ID: 8319208
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of acetyldinaline for treatment of minimal residual disease (MRD): preclinical studies in the BNML rat model for human acute myelocytic leukemia.
el-Beltagi HM; Martens AC; Dahab GM; Hagenbeek A
Leukemia; 1993 Nov; 7(11):1795-800. PubMed ID: 8231248
[TBL] [Abstract][Full Text] [Related]
3. Dinaline: a new oral drug against leukemia? Preclinical studies in a relevant rat model for human acute myelocytic leukemia (BNML).
Hagenbeek A; Weiershausen U; Martens AC
Leukemia; 1988 Apr; 2(4):226-30. PubMed ID: 3163079
[TBL] [Abstract][Full Text] [Related]
4. In vivo development of an acetyldinaline resistant subline of the BN rat acute myelocytic leukemia (BNML).
el-Beltagi HM; Martens AC; Haroun EA; Hagenbeek A
Leukemia; 1993 Aug; 7(8):1275-80. PubMed ID: 8350629
[TBL] [Abstract][Full Text] [Related]
5. AMSA: in vivo log cell kill for leukemic clonogenic cells versus toxicity for normal hemopoietic stem cells in a rat model for human acute myelocytic leukemia (BNML).
Hagenbeek A; Martens AC
Eur J Cancer Clin Oncol; 1986 Oct; 22(10):1255-8. PubMed ID: 3469100
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo effects of acetyldinaline on murine megakaryocytopoiesis.
Volpe DA; LoRusso PM; Foster BJ; Parchment RE
Cancer Chemother Pharmacol; 2004 Jul; 54(1):89-94. PubMed ID: 15014898
[TBL] [Abstract][Full Text] [Related]
7. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
Colly LP; Peters WG; Willemze R
Cancer Res; 1986 Aug; 46(8):3825-7. PubMed ID: 3460691
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline).
Foster BJ; Jones L; Wiegand R; LoRusso PM; Corbett TH
Invest New Drugs; 1997; 15(3):187-94. PubMed ID: 9387041
[TBL] [Abstract][Full Text] [Related]
9. High-dose cyclophosphamide treatment of acute myelocytic leukemia. Studies in the BNML rat model.
Hagenbeek A; Martens AC
Eur J Cancer Clin Oncol; 1982 Aug; 18(8):763-9. PubMed ID: 6759141
[TBL] [Abstract][Full Text] [Related]
10. Cryopreservation of autologous marrow grafts in acute leukemia: survival of in vivo clonogenic leukemic cells and normal hemopoietic stem cells.
Hagenbeek A; Martens AC
Leukemia; 1989 Jul; 3(7):535-7. PubMed ID: 2659904
[TBL] [Abstract][Full Text] [Related]
11. Latent hematopoietic stem cell toxicity associated with protracted drug administration.
Keyes KA; Segovia JC; Bueren JA; Parchment RE; Albella B
Exp Hematol; 2001 Mar; 29(3):286-94. PubMed ID: 11274755
[TBL] [Abstract][Full Text] [Related]
12. Preclinical antitumor activity of CI-994.
LoRusso PM; Demchik L; Foster B; Knight J; Bissery MC; Polin LM; Leopold WR; Corbett TH
Invest New Drugs; 1996; 14(4):349-56. PubMed ID: 9157069
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of doxorubicin for normal hematopoietic and acute myeloid leukemia cells of the rat.
Sonneveld P; Mulder Ja; van Bekkum DW
Cancer Chemother Pharmacol; 1981; 5(3):167-73. PubMed ID: 6945921
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute myelocytic leukemia with interleukin-6 Pseudomonas exotoxin fusion protein in a rat leukemia model.
Rozemuller H; Rombouts WJ; Touw IP; FitzGerald DJ; Kreitman RJ; Pastan I; Hagenbeek A; Martens AC
Leukemia; 1996 Nov; 10(11):1796-803. PubMed ID: 8892684
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond.
Keyes KA; Albella B; LoRusso PM; Bueren JA; Parchment RE
Clin Cancer Res; 2000 Jun; 6(6):2474-81. PubMed ID: 10873102
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of piperazinedione prior to bone marrow transplantation: studies in a rat model for human acute myelocytic leukemia.
Hagenbeek A; Martens AC
Cancer Treat Rep; 1981; 65(7-8):575-82. PubMed ID: 7018679
[TBL] [Abstract][Full Text] [Related]
17. Enhanced tumor load reduction after chemotherapy induced recruitment and synchronization in a slowly growing rat leukemia model (BNML) for human acute myelocytic leukemia.
Colly LP; van Bekkum DW; Hagenbeek A
Leuk Res; 1984; 8(6):953-63. PubMed ID: 6595483
[TBL] [Abstract][Full Text] [Related]
18. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model.
Vaughan WP; Burke PJ
Cancer Res; 1983 May; 43(5):2005-9. PubMed ID: 6572561
[TBL] [Abstract][Full Text] [Related]
19. Toxicity of ASTA Z 7557 (INN mafosfamide) to normal- and leukemic stem cells: implications for autologous bone marrow transplantation.
Hagenbeek A; Martens AC
Invest New Drugs; 1984; 2(2):237-43. PubMed ID: 6381383
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of high-dose cyclophosphamide in combination with total-body irradiation in the treatment of acute myelocytic leukemia: studies in a relevant rat model.
Hagenbeek A; Martens AC
Cancer Res; 1983 Jan; 43(1):408-12. PubMed ID: 6336603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
